Richard Kent, a partner at venture capital firm , is joining the board of directors at startup

Kent replaces Garheng Kong, who recently left Intersouth to join a VC firm in Silicon Valley, as Intersotuh’s board representative.

Kong remains chair of the Cempra board. He now works with Sofinnova Ventures.

Kent has more than 25 years of experience in pharmaceuticals and drug development. He is former chief executive officer of Sernex, which was acquired by Pfizer two years ago.

"Adding Dr. Kent to our board, with his experience both in shepherding [new drug applications] through to regulatory approval and his involvement with Serenex’s transaction with Pfizer, is an important step for Cempra," said Prabhavathi Fernandes, Cempra’s CEO. "We have two differentiated antibiotic candidates in mid-to-late stage clinical development. His advice will be invaluable as both of our antibiotics move forward towards an NDA as well as assisting us with our partnering strategy."

Get the latest news alerts: at Twitter.